Bayesian optimal designs for dose-response curves with common parameters

11/15/2017
by   Kirsten Schorning, et al.
0

The issue of determining not only an adequate dose but also a dosing frequency of a drug arises frequently in Phase II clinical trials. This results in the comparison of models which have some parameters in common. Planning such studies based on Bayesian optimal designs offers robustness to our conclusions since these designs, unlike locally optimal designs, are efficient even if the parameters are misspecified. In this paper we develop approximate design theory for Bayesian D-optimality for nonlinear regression models with common parameters and investigate the cases of common location or common location and scale parameters separately. Analytical characterisations of saturated Bayesian D-optimal designs are derived for frequently used dose-response models and the advantages of our results are illustrated via a numerical investigation.

READ FULL TEXT

page 1

page 2

page 3

page 4

research
03/01/2022

Oncology Dose Finding Using Approximate Bayesian Computation Design

In the development of new cancer treatment, an essential step is to dete...
research
11/24/2021

A Unified Decision Framework for Phase I Dose-Finding Designs

The purpose of a phase I dose-finding clinical trial is to investigate t...
research
02/09/2019

Equivalence of regression curves sharing common parameters

In clinical trials the comparison of two different populations is a freq...
research
03/11/2020

Optimal dose calibration in radiotherapy

In this paper, the tools provided by the theory of Optimal Experimental ...
research
12/16/2020

Optimizing the Parameters of A Physical Exercise Dose-Response Model: An Algorithmic Comparison

The purpose of this research was to compare the robustness and performan...
research
09/11/2023

Statistical and Practical Considerations in Planning and Conduct of Dose Optimization Trials

The US Food and Drug Administration launched Project Optimus with the ai...
research
02/20/2021

Adaptive dose-response studies to establish proof-of-concept in learning-phase clinical trials

In learning-phase clinical trials in drug development, adaptive designs ...

Please sign up or login with your details

Forgot password? Click here to reset